CD4 and melanoma: For T cells, triptolide is reported to overturn T cell suppression, particularly CD4+ T cells subset in glioma (T98G) cells under IFN-γ treatment, while significantly decreases the proportion of Tregs in the spleen and axillary lymph nodes of melanoma (B16-F10) bearing mice, thereby impairing their suppressive function through the down-regulation of Foxp3, IL-10, and transforming growth factor in both protein and mRNA levels [974, 975].